Literature DB >> 33544339

MicroRNA signature in classical Hodgkin lymphoma.

Julia Paczkowska1, Maciej Giefing2.   

Abstract

Classical Hodgkin lymphoma (cHL) is one of the most prevalent lymphomas with a unique cell composition compared to other lymphoma entities. Rare, malignant Hodgkin and Reed-Sternberg (HRS) cells embedded with an extensive but ineffective immune infiltration were previously characterized by a large number of genetic and epigenetic alterations. Recently, microRNA profiling studies highlighted the importance of small non-coding RNA in cHL. This review summarizes available literature data and provides a detailed comparison of four studies where cHL cell lines and microdissected HRS cells were used. Several microRNAs were found to be consistently up- (let-7-f, mir-9, mir-21, mir-23a, mir-27a, mir-155, and mir-196a) or downregulated (mir-138 and mir-150) in cHL. These deregulated microRNAs are involved in the processes crucial for cHL pathogenesis, such as impaired B cell development (mir-9, mir-150, and mir-155), NFκB hyperactivation (mir-155 and mir-196a), and immune evasion (mir-138). Therefore, the deregulation of microRNA expression can be considered a complementary mechanism to genetic alterations promoting lymphomagenesis. Moreover, the expression of let-7f, mir-9 and mir-27a is specific for cHL and can serve as a biomarker to distinguish this lymphoma from other B cell lymphomas. However, additional in-depth and high throughput analysis of microRNA expression in HRS cells is necessary to decipher the complete picture of microRNA in cHL.

Entities:  

Keywords:  Epigenetics; HRS; cHL; microRNA

Year:  2021        PMID: 33544339     DOI: 10.1007/s13353-021-00614-7

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   3.240


  2 in total

1.  MicroRNA‑27a promotes tumorigenesis via targeting AKT in triple negative breast cancer.

Authors:  Jing Wu; Zhihui Sun; Huijie Sun; Yanhua Li
Journal:  Mol Med Rep       Date:  2017-10-26       Impact factor: 2.952

2.  Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients.

Authors:  Monique Aj van Eijndhoven; Josée M Zijlstra; Nils J Groenewegen; Esther Ee Drees; Stuart van Niele; S Rubina Baglio; Danijela Koppers-Lalic; Hans van der Voorn; Sten Fwm Libregts; Marca Hm Wauben; Renee X de Menezes; Jan Rt van Weering; Rienk Nieuwland; Lydia Visser; Anke van den Berg; Daphne de Jong; D Michiel Pegtel
Journal:  JCI Insight       Date:  2016-11-17
  2 in total
  2 in total

Review 1.  Implication of microRNAs in Carcinogenesis with Emphasis on Hematological Malignancies and Clinical Translation.

Authors:  Zsuzsanna Gaál
Journal:  Int J Mol Sci       Date:  2022-05-23       Impact factor: 6.208

Review 2.  MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes.

Authors:  Cyril Sobolewski; Laurent Dubuquoy; Noémie Legrand
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.